For John Lauerman's latest contributions to The Japan Times, see below:
As infections surge by more than 300,000 cases for 14 straight days, India’s limited ability to track new mutations emerging from its outbreak is a growing concern for scientists.
Health officials are exploring whether and how an immune reaction may occur in people who have received vaccines made by AstraZeneca and Johnson & Johnson.
Even with the latest technologies, money and might behind the unprecedented global drive to knock out COVID-19, the disease is unlikely to be eliminated any time soon.
Tedros Adhanom Ghebreyesus has perhaps the most thankless job in global public health. As director-general of the World Health Organization, the former Ethiopian health minister is racing against time to prevent a dangerous new coronavirus in China from precipitating a worldwide pandemic. Yet containing and ...
A drug-pricing plan unveiled by the Trump administration has put the U.S. on a path toward policies like those in Europe, where governments use tight cost controls. Under the proposal, announced at an event at the Department of Health and Human Services on Thursday, President ...
Shares of Takeda Pharmaceutical Co. fell the most in nine years after the firm disclosed it is considering a bid for Shire PLC that could approach $50 billion (about ¥5.3 trillion), which would be the Japanese company’s biggest takeover ever. The decline in early Tokyo ...
